Lumexa Imaging (LMRI) is a Healthcare company in the Medical Devices industry. It has a market capitalization of $1.29B and a free-cash-flow yield of -0.7%. Over the most recent reported fiscal year, revenue grew 7.8% and free cash flow per share fell 148.5%. Nama's AI scorecard rates it Sell, 4.1 out of 10.
AI scorecard
Sell · 4.1/10
Negative, at the mild end of Sell. As of Nov 7, 2026.
Shariah screen
Not Shariah Compliant
At least one of the three ratios or the industry test failed.
Off its high
-30.9%
How far the last close sits under the highest price of the past five years.
Market cap
$1.29B
Trailing P/E
—
Price / book
2.1
Price / sales
1.2
FCF yield
-0.7%
Dividend yield
—
Gross margin
14.9%
Operating margin
1.4%
Net margin
-2.7%
Revenue growth (YoY)
+7.8%
Revenue growth (3-yr annual)
—
EPS growth (YoY)
—
FCF/share growth (YoY)
-148.5%
Beta
—
Exchange
NASDAQ
Sector
Healthcare
Industry
Medical Devices
LMRI earnings
Next report: Nov 10, 2026 (Q3 2026, EPS estimate $0.18).
Beat the EPS estimate in 1 of 2 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q2 2026
Aug 12, 2026
$0.20
$0.14
+42.9%
$264.16M
Q4 2025
Mar 26, 2026
$0.01
$0.05
-80.0%
$267.73M
LMRI analyst price target
Median target $18.00 from 9 analysts, ranging $13.00 – $23.00.
Nama's AI scorecard currently rates Lumexa Imaging Sell (4.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does LMRI report earnings?
Lumexa Imaging's next scheduled report is on Nov 10, 2026. Analysts expect EPS of $0.18.
What is the LMRI price target?
The median analyst price target from 9 analysts is $18.00, with a range of $13.00 – $23.00.
Is LMRI Shariah compliant?
Nama's AAOIFI-style screen reads Lumexa Imaging as Not Shariah Compliant. At least one of the three ratios or the industry test failed.